Emvision Medical Devices Ltd. unveiled a portable brain scanning helmet for first responders to quickly identify whether a patient is experiencing a stroke and, if so, what type.

Swiss scientists developed hydrogel implants that could help prevent and treat endometriosis by blocking the fallopian tubes and stopping the passage of endometrial cells. The implants, though in their early stage of development, bode well for the millions of women suffering from the chronic condition.

Novocuff Inc. closed an oversubscribed $26 million series A funding round to support further development of the Novocuff cervical control system, which is designed to reduce preterm births by closing the cervix in high-risk pregnancies. The funds will enable the company to undertake a U.S. multi-center pivotal clinical trial, pursue marketing authorization, expand its team and begin early-stage commercialization of the device.

Beyond its success in migraine and attention deficit hyperactivity disorder, Nu Eyne Co. Ltd. is advancing a portfolio of noninvasive, wearable trigeminal nerve stimulation devices across key three areas of neuromodulation, tissue regeneration and proliferation inhibition.

Setpoint Medical Corp. reported positive topline results from its landmark RESET-RA study. The study evaluated the Setpoint system as a potential new neuroimmune modulation treatment for adults living with moderate-to-severe rheumatoid arthritis who are incomplete responders or are intolerant to biologic or targeted synthetic disease-modifying anti-rheumatic drugs.

Pulse Biosciences Inc. received U.S. FDA breakthrough device designation for its Cellfx cardiac surgery system with surgical clamp for ablation of atrial fibrillation. The Cellfx system uses nanosecond pulsed field ablation technology to deliver durable, continuous transmural ablation.

South Korean researchers from Gwangju Institute of Science and Technology invented SPINDLE — a virtual reality-based robotic rehabilitation system — as a potential breakthrough therapy for tremor patients.

The years’ long effort by activist investor Politan Capital Management LP to take control of the Masimo Corp. board of directors and oust Masimo CEO and founder Joe Kiani took a turn for the weird this week as news emerged that Masimo Chief Operating Officer Bilal Muhsin notified the board that he would step down if Kiani were pushed out.

The U.S. FDA granted Signum Surgical Ltd. de novo marketing clearance for its Biohealx technology as a treatment for anal fistula. Biohealx is a single use, bioabsorbable implant, designed to not only to treat the condition in a minimally invasive procedure but also promote healing, prevent fistula recurrence and protect patient continence.

In the first patenting to have been published in the name of Lo Biosciences Inc., the company’s co-founder and CEO Sasank Vemulapati seeks further protection for their development of a device and method that helps eliminate time, distance, and cost as barriers between patients and their next blood test, by allowing patients to collect laboratory quality blood samples at home without the assistance of any health care professionals.